Clinical trial results promising for people with the debilitating disorder A clinical trial at UC Davis Health and six other sites showed that a cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy (DMD), a rare genetic disorder causing muscle loss and physical impairments in young people. The therapy appears to be safe and effective
A clinical trial conducted by researchers from RCSI University of Medicine and Health Sciences and Beaumont Hospital Dublin has indicated an effective treatment for critically ill COVID-19 patients. The study, published today in Med, investigates the effects of using an anti-inflammatory protein, alpha-1 antitryspin (AAT), to treat COVID-19 patients who have progressed to acute respiratory distress
Two studies published this week have added to a growing body of evidence linking covid infection to subsequent cognitive impairment, even in cases of less severe disease. One study, a preprint published in Nature, examined 785 UK Biobank participants aged 51-81 who routinely receive brain scans and cognitive testing as part of the Biobank’s data gathering. About
The hemostatic system in cancer The hemostatic system forms an integral part of the innate immune system and contributes to tumor growth and metastasis. Many malignancies are associated with a hyper-thrombotic state that derives foremost from tissue factor (TF), the initiator of the coagulation cascade, expressed by tumor cells and innate immune cells and stromal
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that baricitinib, an anti-inflammatory treatment normally used to treat rheumatoid arthritis, reduces the risk of death when given to hospitalised patients with severe COVID-19. The benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to
Cardiovascular care essential part of post-infection care An analysis of federal health data indicates that people who have had COVID-19 are at increased risk of developing cardiovascular complications within the first month to a year after infection, according to researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis
CAR T therapy has had enormous impact in some areas of oncology, and notable efforts are underway to extend the success to additional forms of cancer. However, the use of engineered T cells may be evenmore attractive for disorders other than cancer for several reasons. This review analyses different opportunities and future directions. First, for
